Intracellular trafficking of new anticancer therapeutics: antibody-drug conjugates

被引：111

作者：

Kalim, Muhammad ^{[1
]}

Chen, Jie ^{[1
]}

Wang, Shenghao ^{[1
]}

Lin, Caiyao ^{[1
]}

Ullah, Saif ^{[1
]}

Liang, Keying ^{[1
]}

Ding, Qian ^{[1
]}

Chen, Shuqing ^{[2
]}

Zhan, Jinbiao ^{[1
]}

机构：

[1] Zhejiang Univ, Sch Med, Dept Biochem & Genet, 866 Yuhangtang Rd, Hangzhou, Zhejiang, Peoples R China

[2] Zhejiang Univ, Coll Pharmaceut Sci, Dept Pharmaceut Anal, Hangzhou, Zhejiang, Peoples R China

来源：

DRUG DESIGN DEVELOPMENT AND THERAPY | 2017年 / 11卷

关键词：

antibody-drug conjugate; antibody; endocytosis; intracellular trafficking; clathrin; GLEMBATUMUMAB VEDOTIN CDX-011; POTENT ANTITUMOR-ACTIVITY; MONOMETHYL AURISTATIN E; IN-VIVO; GEMTUZUMAB OZOGAMICIN; TRASTUZUMAB EMTANSINE; BRENTUXIMAB VEDOTIN; LORVOTUZUMAB MERTANSINE; INOTUZUMAB OZOGAMICIN; BREAST-CANCER;

D O I：

10.2147/DDDT.S135571

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Antibody-drug conjugate (ADC) is a milestone in targeted cancer therapy that comprises of monoclonal antibodies chemically linked to cytotoxic drugs. Internalization of ADC takes place via clathrin-mediated endocytosis, caveolae-mediated endocytosis, and pinocytosis. Conjugation strategies, endocytosis and intracellular trafficking optimization, linkers, and drugs chemistry present a great challenge for researchers to eradicate tumor cells successfully. This inventiveness of endocytosis and intracellular trafficking has given considerable momentum recently to develop specific antibodies and ADCs to treat cancer cells. It is significantly advantageous to emphasize the endocytosis and intracellular trafficking pathways efficiently and to design potent engineered conjugates and biological entities to boost efficient therapies enormously for cancer treatment. Current studies illustrate endocytosis and intracellular trafficking of ADC, protein, and linker strategies in unloading and also concisely evaluate practically applicable ADCs.

引用

收藏

页码：2265 / 2276

页数：12

相关论文

共 129 条

[1] Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action [J].

Abal, M. ;

Andreu, J. M. ;

Barasoain, I. .

CURRENT CANCER DRUG TARGETS, 2003, 3 (03) :193-203

[2] Antibody-drug conjugates - a perfect synergy [J].

Adair, John R. ;

Howard, Philip W. ;

Hartley, John A. ;

Williams, David G. ;

Chester, Kerry A. .

EXPERT OPINION ON BIOLOGICAL THERAPY, 2012, 12 (09) :1191-1206

[3] Safety, Pharmacokinetics, and Preliminary Clinical Activity of Inotuzumab Ozogamicin, a Novel Immunoconjugate for the Treatment of B-Cell Non-Hodgkin's Lymphoma: Results of a Phase I Study [J].

Advani, Anjali ;

Coiffier, Bertrand ;

Czuczman, Myron S. ;

Dreyling, Martin ;

Foran, James ;

Gine, Eva ;

Gisselbrecht, Christian ;

Ketterer, Nicolas ;

Nasta, Sunita ;

Rohatiner, Ama ;

Schmidt-Wolf, Ingo G. H. ;

Schuler, Martin ;

Sierra, Jorge ;

Smith, Mitchell R. ;

Verhoef, Gregor ;

Winter, Jane N. ;

Boni, Joseph ;

Vandendries, Erik ;

Shapiro, Mark ;

Fayad, Luis .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (12) :2085-2093

[4] Bridging membrane and cytoskeleton dynamics in the secretory and endocytic pathways [J].

Anitei, Mihaela ;

Hoflack, Bernard .

NATURE CELL BIOLOGY, 2012, 14 (01) :11-19

[5] Oxidizing potential of endosomes and lysosomes limits intracellular cleavage of disulfide-based antibody-drug conjugates [J].

Austin, CD ;

Wen, XH ;

Gazzard, L ;

Nelson, C ;

Scheller, RH ;

Scales, SJ .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (50) :17987-17992

[6]

Bander NH, 2013, METHODS MOL BIOL, V1045, P29, DOI 10.1007/978-1-62703-541-5_2

[7] Trastuzumab emtansine: mechanisms of action and drug resistance [J].

Barok, Mark ;

Joensuu, Heikki ;

Isola, Jorma .

BREAST CANCER RESEARCH, 2014, 16 (02)

[8] Connections between chemical constitution and desinfection effect. Article on the study of "inner antisepsis" [J].

Bechhold, H ;

Ehrlich, P .

HOPPE-SEYLERS ZEITSCHRIFT FUR PHYSIOLOGISCHE CHEMIE, 1906, 47 (2/3) :173-199

[9] The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model [J].

Beckwith, K. A. ;

Frissora, F. W. ;

Stefanovski, M. R. ;

Towns, W. H. ;

Cheney, C. ;

Mo, X. ;

Deckert, J. ;

Croce, C. M. ;

Flynn, J. M. ;

Andritsos, L. A. ;

Jones, J. A. ;

Maddocks, K. J. ;

Lozanski, G. ;

Byrd, J. C. ;

Muthusamy, N. .

LEUKEMIA, 2014, 28 (07) :1501-1510

[10] First-in-human phase I dose escalation study of a novel anti-mesothelin antibody drug conjugate (ADC), BAY 94-9343, in patients with advanced solid tumors. [J].

Bendell, Johanna ;

Blumenschein, George ;

Zinner, Ralph ;

Hong, David ;

Jones, Suzanne ;

Infante, Jeffrey ;

Burris, Howard ;

Rajagopalan, Prabhu ;

Kornacker, Martin ;

Henderson, David ;

Kelly, Andrea ;

Hassan, Raffit .

CANCER RESEARCH, 2013, 73 (08)

← 1 2 3 4 5 6 7 8 9 10 →